Company intelligence / Profile preview

Nelum

Cary, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Nelum is a clinical-stage biopharmaceutical company focused on developing best-in-class patented molecules to target fibrosis and various forms of cancer. The company's lead asset, NLM-001 (formerly TAK-441, in-licensed from Takeda), is a small molecule hedgehog inhibitor that targets cancer-associated fibroblasts to disrupt the tumor microenvironment. Nelum is evaluating NLM-001 in clinical trials for advanced pancreatic cancer in combination with chemotherapy and immunotherapy. Additionally, through its subsidiary Ventalis Pharma, Nelum is developing NLM-001 (as VEN-001) for the treatment of pulmonary fibrosis.

Therapeutic areas: OncologyPulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

AgenusTakeda

Beyond the preview

Go deeper on Nelum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nelum.

Explore the full profile